- Silo Wellness announced that trading its common shares on the Canadian Securities Exchange (“CSE”) will commence under the ticker symbol “SILO”.
SILO WELLNESS INC., (SILO), is pleased to announce that trading its common shares on the Canadian Securities Exchange (“CSE”) will commence today under the ticker symbol “SILO”. In accordance with the policies of the CSE, Silo Wellness has filed its CSE Form 2A Listing Statement on SEDAR, which provides for additional information regarding Silo Wellness’ business operations.
“We are delighted to be trading on the CSE as the next step in Silo Wellness’ journey in the functional mushroom and psychedelics marketplaces and celebrate this important milestone with the team who have worked so diligently to bring Silo Wellness to the public markets. By listing on the CSE, investors will now be able to participate in the growth of Silo Wellness as we execute on our business model in Oregon, Jamaica and beyond.”
Douglas K. Gordon – Chief Executive Officer of Silo Wellness
About Silo Wellness
The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe, and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.
Since inception, Silo Wellness’ activities have focused on: (1) development of psilocybin-free functional mushroom tinctures, (2) the development of the formulation of a psilocybin nasal spray in Jamaica and (3) offering of Jamaican and Oregon psychedelic wellness retreats and Jamaican cultivation of psychedelic mushrooms. None of Silo Wellness’ products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.
Further Information
For further information, please contact: